Skip to main content

Table 1 Patient characteristics (n = 145)

From: Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study

Variable

Value

Age years, mean (sd)

76.5 (7.0)

ECOG performance status, No. (%) (missing = 14)

 0–1

125 (95)

  > 2

6 (5)

Presence of Pain, yes, n (%)

56 (38.6)

Brief Pain Inventory Question #3, >2, n (%), (missing =13)

46 (34.9)

Baseline PSA, median (range)

17.4 (0.4 to 2100.0)

Baseline ALT, median (range)

20 (8–87)

Baseline AST, median (range)

18.5 (6–309)

Gleason at time of initial diagnosis, n (%) (missing = 4)

  > 7

81 (57.5)

Local treatment, n (%)

 None

58 (40.0)

 External Beam Radiation Therapy

25 (17.2)

 Radical Prostatectomy

49 (33.8)

 Both

13 (8.9)

Disease location, n (%) (missing =5)

 Bone only

75 (53.5)

 Lymph nodes only

22 (15.7)

 Visceral only

4 (2.8)

 Prostatic fossa only

11 (7.8)

 Multiple sites

28 (20.0)

Comorbidity, n (%)

 None

33 (22.7)

 Cardiovascular only

50 (35.7)

 Metabolic only

8 (5.5)

 Multiple (cardiovascular + metabolic)

26 (17.9)

 Other

28 (19.3)

Time to mCRPC from initial diagnosis years, median (range)

5.0 (0.2 to 17.7)

Hormonal manipulations before AA >2, n (%)

22 (15.2)

Duration of ADT >12 m, n (%)

113 (77.9)

  1. Abreviations: mCRPC metastatic castration resistant prostate cancer, ECOG Eastern Cooperative Oncology Group, PSA prostate specific antigen, AA abiraterone acetate, ALT alanine aminotransferase, AST aspartate aminotransferase, ADT androgen deprivation therapy